CRP and tuberculosis: The time to target patients beyond just those with symptoms already at facilities is more feasible and compelling than ever, and the speed at which excellent COVID-19 tests were developed puts into greater perspective the inertia in not only new TB test development but also the lagging deployment of already existing tools that could save the lives of people suffering from TB now (e.g., CRP, dCXR with CAD).